Management of Hepatic Encephalopathy Associated with Advanced Liver Disease
- PMID: 35536537
- PMCID: PMC9205788
- DOI: 10.1007/s40261-022-01146-6
Management of Hepatic Encephalopathy Associated with Advanced Liver Disease
Abstract
Hepatic encephalopathy (HE) is a very prevalent condition in patients with advanced liver disease and has a high recurrence rate. The pathophysiology has a multifactorial origin where hyperammonaemia and inflammation become particularly relevant. There are no HE-specific diagnostic tests, and diagnosis is usually made by taking into account the presence of suggestive and compatible clinical symptoms, the existence of a predisposing liver condition and ruling out other causes with similar clinical manifestations. Once the diagnosis of HE is established, it is essential to carry out an adequate classification based on the underlying liver disease, the intensity of clinical manifestations, the temporal course of the disease and the presence or absence of precipitating factors. Treatment should be aimed at decreasing the duration, intensity and consequences of episodes, preventing recurrence and limiting the impact of the disease in patients and their relatives.
© 2022. The Author(s).
Conflict of interest statement
The authors declare that there were no conflicts of interest.
Figures


Similar articles
-
Current approaches to hepatic encephalopathy.Ann Hepatol. 2022 Nov-Dec;27(6):100757. doi: 10.1016/j.aohep.2022.100757. Epub 2022 Sep 14. Ann Hepatol. 2022. PMID: 36115576 Review.
-
[Hepatic encephalopathy in patients with cirrhosis: new aspects and practical recommendations].Rev Med Suisse. 2010 Sep 8;6(261):1667-71. Rev Med Suisse. 2010. PMID: 20939401 French.
-
The assessment and care of patients with hepatic encephalopathy.Br J Nurs. 2017 Jul 13;26(13):724-729. doi: 10.12968/bjon.2017.26.13.724. Br J Nurs. 2017. PMID: 28704077
-
Current concepts in the assessment and treatment of hepatic encephalopathy.QJM. 2010 Jan;103(1):9-16. doi: 10.1093/qjmed/hcp152. Epub 2009 Nov 10. QJM. 2010. PMID: 19903725 Review.
-
Hepatic Encephalopathy: Diagnosis and Treatment in Advanced Liver Disease.Crit Care Nurs Clin North Am. 2022 Sep;34(3):331-339. doi: 10.1016/j.cnc.2022.04.011. Crit Care Nurs Clin North Am. 2022. PMID: 36049852 Review.
Cited by
-
Serum Cytokeratin-18 levels as a prognostic biomarker in advanced liver disease: a comprehensive meta-analysis.Clin Exp Med. 2024 Jul 18;24(1):160. doi: 10.1007/s10238-024-01423-y. Clin Exp Med. 2024. PMID: 39023658 Free PMC article.
-
Stem cell transplantation therapy for advanced liver damage-associated neurodegenerative disorders.Int J Surg. 2024 Nov 1;110(11):6873-6882. doi: 10.1097/JS9.0000000000002001. Int J Surg. 2024. PMID: 39699862 Free PMC article. Review.
-
D-dimer is a prognostic marker for 1-year mortality in patients with chronic liver failure and hepatic encephalopathy.Hepatol Forum. 2024 Sep 11;5(4):193-197. doi: 10.14744/hf.2023.2023.0065. eCollection 2024. Hepatol Forum. 2024. PMID: 39355833 Free PMC article.
-
Foreword.Clin Drug Investig. 2022 Jun;42(Suppl 1):1-2. doi: 10.1007/s40261-022-01148-4. Epub 2022 May 9. Clin Drug Investig. 2022. PMID: 35532834 Free PMC article. No abstract available.
-
Recurrent Mental Status Changes in a Patient With Chronic Alcoholic Cirrhosis Taking Diuretics: A Case Report.Cureus. 2023 Nov 3;15(11):e48221. doi: 10.7759/cureus.48221. eCollection 2023 Nov. Cureus. 2023. PMID: 38050499 Free PMC article.
References
-
- Nolte W, Wiltfang J, Schindler C, et al. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology. 1998;28(5):1215–1225. doi: 10.1002/hep.510280508. - DOI - PubMed
-
- Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomised controlled trial of lactulose versus placebo. Gastroenterology. 2009;137(885–91):891.e1. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources